Lamisil

Terbinafine, the active ingredient in Lamisil, is an allylamine antifungal presented as a topical formulation for skin application. It is used to treat superficial fungal infections such as athlete’s foot, ringworm and jock itch in both adults and children.

GNH USA supplies Lamisil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand through reliable logistics networks.

Lamisil (terbinafine) is employed to treat superficial dermatophyte infections affecting the skin. - Tinea pedis: reduces fungal growth and relieves itching and scaling on the feet. - Tinea corporis: clears ring‑shaped lesions on the body by eradicating the causative dermatophytes. - Tinea cruris: treats fungal infection of the groin area, diminishing redness and discomfort. - Other superficial dermatophyte infections: resolves fungal involvement of nails, scalp or other skin sites when indicated.

Topical terbinafine may cause local and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Burning sensation: mild heat or stinging at the application site. - Itching: transient pruritus around the treated area. - Redness: localized erythema that usually resolves with continued use. - Dryness or peeling: skin may become flaky or dry. - Irritation: mild discomfort or rash limited to the site of application.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, hives, or difficulty breathing indicating possible anaphylaxis. - Contact dermatitis: intense redness, swelling, and blistering requiring discontinuation. - Hepatotoxicity: rare systemic absorption leading to elevated liver enzymes. - Stevens‑Johnson syndrome: extensive skin detachment and mucosal involvement, a medical emergency. - Persistent ulceration: non‑healing skin breakdown at the application site.

Before using Lamisil, consider the following safety measures to minimize risks. - Assess allergy: avoid use if known hypersensitivity to terbinafine or other allylamines. - Limit duration: follow prescriber’s recommended treatment length to reduce irritation. - Avoid broken skin: do not apply on extensive open wounds or severe dermatitis. - Monitor liver function: patients with pre‑existing liver disease should have baseline tests. - Pediatric use: use only under medical supervision in children as safety data are limited. - Store at room temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Terbinafine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Cytochrome P450 inhibitors: concurrent strong CYP2D6 inhibitors may increase systemic terbinafine levels. - Antifungal agents: combining with other systemic antifungals can raise risk of hepatotoxicity. - Certain antidepressants: co‑administration with sertraline may enhance photosensitivity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: terbinafine may reduce hormonal efficacy; advise alternative contraception. - Warfarin: monitor INR as terbinafine may potentiate anticoagulant effect. - Rifampin: may decrease terbinafine concentrations, reducing antifungal activity.